Stimulation of erythropoiesis by thalidomide in multiple myeloma patients: its influence on FasL, TRAIL and their receptors on erythroblasts
作者： Anna Dmoszynska , Marek Hus , Norbert Grzasko , Maria Soroka-Wojtaszko
DOI: 10.3324/%X
关键词: Internal medicine 、 Receptor 、 Fas ligand 、 Hematology 、 Endocrinology 、 Erythropoiesis 、 Thalidomide 、 Medicine 、 Tumor necrosis factor alpha 、 Apoptosis 、 Multiple myeloma
摘要: The expression of proteins the tumor necrosis factor (TNF) family on erythroblasts was measured during thalidomide treatment in 29 patients with multiple myeloma (MM). A clinical response observed 17 (58.6%) and haemoglobin concentration increased 22 (75.9%). FasL, Fas, TNF-related apoptosis-inducing ligand (TRAIL) TRAIL-R1 decreased significantly treatment. Additional vitro studies revealed that apoptosis TRAIL, TRAIL-R2 lower cultures than control cultures. Altogether our results suggest may stimulate erythropoiesis MM by decreasing TNF-like ligands/receptors erythroblasts.
haematologica.org
sci-hub.st 参考文章(18)
R. De Maria, U. Testa, L. Luchetti, A. Zeuner, G. Stassi, E. Pelosi, R. Riccioni, N. Felli, P. Samoggia, C. Peschle, Apoptotic Role of Fas/Fas Ligand System in the Regulation of Erythropoiesis Blood. ,vol. 93, pp. 796- 803 ,(1999) , 10.1182/BLOOD.V93.3.796
Giorgio Zauli, Paola Secchiero, Alessandra Bassini, Lia Guidotti, Sabina Pierpaoli, Marco Vitale, Emad S. Alnemri, Stefano Papa, Loris Zamai, TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis Blood. ,vol. 95, pp. 3716- 3724 ,(2000) , 10.1182/BLOOD.V95.12.3716
Franco Silvestris, Marco Tucci, Paola Cafforio, Franco Dammacco, Fas-L up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression Blood. ,vol. 97, pp. 1155- 1164 ,(2001) , 10.1182/BLOOD.V97.5.1155
R. J. D'Amato, M. S. Loughnan, E. Flynn, J. Folkman, Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 91, pp. 4082- 4085 ,(1994) , 10.1073/PNAS.91.9.4082
Jerome B. Zeldis, Bruce A. Williams, Steve D. Thomas, Marc E. Elsayed, S.t.e.p.s. : A comprehensive program for controlling and monitoring access to thalidomide Clinical Therapeutics. ,vol. 21, pp. 319- 330 ,(1999) , 10.1016/S0149-2918(00)88289-2
Anna Dmoszyńska, Agnieszka Bojarska-Junak, Damian Domański, Jacek Roliński, Marek Hus, Maria Soroka-Wojtaszko, Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma. Leukemia & Lymphoma. ,vol. 43, pp. 401- 406 ,(2002) , 10.1080/10428190290006224
Kneller, Raanani, Hardan, Avigdor, Levi, Berkowicz, Ben-Bassat, Therapy with thalidomide in refractory multiple myeloma patients — the revival of an old drug British Journal of Haematology. ,vol. 108, pp. 391- 393 ,(2000) , 10.1046/J.1365-2141.2000.01835.X
Tsunayuki Kakimoto, Yutaka Hattori, Shinichiro Okamoto, Norihide Sato, Tamihiro Kamata, Masaya Yamaguchi, Kunihiko Morita, Taketo Yamada, Nobuyuki Takayama, Hideo Uchida, Naoki Shimada, Yusuke Tanigawara, Yasuo Ikeda, Thalidomide for the treatment of refractory multiple myeloma: association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome. Japanese Journal of Cancer Research. ,vol. 93, pp. 1029- 1036 ,(2002) , 10.1111/J.1349-7006.2002.TB02480.X
Tom L. Rowland, Simon M. McHugh, John Deighton, Rebecca J. Dearman, Pamela W. Ewan, Ian Kimber, Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells Immunopharmacology. ,vol. 40, pp. 11- 20 ,(1998) , 10.1016/S0162-3109(98)00010-1
Franco Silvestris, Paola Cafforio, Marco Tucci, Franco Dammacco, Negative regulation of erythroblast maturation by Fas-L+/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma Blood. ,vol. 99, pp. 1305- 1313 ,(2002) , 10.1182/BLOOD.V99.4.1305